(Adds detail from statement)
PARIS, OCT 3 - French drugmaker Ipsen on Monday
said partner Inspiration Biopharmaceuticals had been informed
that the European Medicines Agency (EMA) had accepted a filing
for a bleeding-prevention treatment for hemophiliacs, triggering
a milestone payment for Inspiration.
The EMA's acceptance for review of the IB1001 treatment
means Ipsen will pay $35 million to Inspiration, in exchange for
a convertible note that will boost Ipsen's stake in its partner
to approximately 38 percent, Ipsen said in a statement.
IB1001 is an intravenous product being developed for the
treatment and prevention of bleeding in individuals with
hemophilia B. In Europe the treatment has completed Phase III
testing, while clinical testing for a U.S. regulatory submission
The treatment will launch in Europe pending regulatory
approval expected in late 2012, Ipsen Chief Executive Marc de
Garidel said in the statement.
(Reporting by Lionel Laurent)